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Abstract: Chronic obstructive pulmonary disease (COPD) is an epidemic in many parts of the 
world. Most patients with COPD demonstrate mild disease. The cornerstone of management of 
mild disease is smoking cessation, which is the only proven intervention to relieve symptoms, 
modify its natural history and reduce mortality. For asymptomatic patients, it is the only 
required therapy. Short-acting bronchodilators can be added on an as needed basis for those 
with intermittent symptoms and regularly for those with persistent symptoms. Long-acting 
bronchodilators can be substituted for those who remain symptomatic despite regular use of 
short-acting bronchodilators. Inhaled corticosteroids do not modify the natural history of COPD 
and as such cannot be recommended as standalone therapy for mild COPD. However, for patients 
with refractory and intractable symptoms, they may be used in combination with long-acting 
beta-2 agonists. Inﬂ  uenza and pneumococcal vaccination and pulmonary rehabilitation are 
other therapies that may be considered for select patients with mild disease. In this paper, 
we summarize the current standard of care for patients with mild COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is an inﬂ  ammatory disorder of the 
lung that is characterized by irreversible or partially reversible airﬂ  ow limitation 
(Rabe et al 2007). It is highly prevalent affecting 600 million people worldwide 
and accounting for nearly 4 million deaths annually (Murray and Lopez 1997b). 
Over the next 20 years, the burden of COPD is expected to increase, making it 
the third leading cause of mortality worldwide (currently fourth) (Murray and 
Lopez 1997a). COPD is a relentless and progressive disease, caused by a complex 
interaction between genes and environment. Although cigarette smoking is the 
single most important risk factor, smokers constitute only ∼50% of the worldwide 
cases of COPD; the rest occur in life-time never smokers (Mannino and Buist 
2007). Furthermore, once COPD develops, smoking cessation does not abrogate 
the increased risk of morbidity and mortality (though the risk is smaller than 
when they were actively smoking) (Anthonisen et al 2005; Pelkonen et al 2000; 
Sin et al 2005b) and smoking cessation does not halt the underlying inﬂ  amma-
tory process in the lungs of COPD patients (Willemse et al 2005). Other known 
risk factors for COPD include airway hyperresponsiveness, genetic abnormalities 
such as alpha-1-antitrypsin deﬁ  ciency, air pollution, biomass smoke exposure, 
occupational dusts and chemicals, respiratory infections especially during child-
hood, and poor nutrition (Chapman et al 2006). Unfortunately, there is a dearth of 
therapies that can effectively modify disease activity or progression. The current 
treatment is largely aimed at relieving patient symptoms and reducing long-term 
complications (Sin et al 2003) and is modiﬁ  ed by disease severity (Rabe et al 2007). International Journal of COPD 2008:3(4) 564
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The management algorithms for moderate to severe COPD 
have been reviewed expertly elsewhere (Sin et al 2003; 
Wilt et al 2007). In this paper, we will review the manage-
ment goals and strategies for patients with mild COPD.
Deﬁ  nition of mild COPD
COPD is diagnosed clinically based on history and 
physical examination, complemented by spirometric data 
demonstrating irreversible or poorly reversible airflow 
obstruction in the absence of an alternate diagnosis such as 
congestive heart failure, neuromuscular disease or asthma 
(Man et al 2003). Most but not all patients with COPD 
are either current or ex-smokers with at least 10 pack-year 
smoking history (pack-years is calculated by multiplying the 
number of cigarettes smoked per day by the years smoked 
divided by 20). The most common presenting symptom 
is dyspnea with exertion or chronic cough with or without 
sputum production. Other (but more infrequent) symptoms 
include chest pain, orthopnea and wheezing. However, 
there is also a group of patients with abnormal spirometry 
but are otherwise asymptomatic. The physical examination 
is completely unremarkable in most patients with mild 
COPD. In some cases, however, patients may demonstrate 
a positive cough test (which is deﬁ  ned as recurrent coughing 
after patients take a deep breath to maximal lung capacity 
and coughs more than once), and have a forced expiratory 
time at the bedside of 9 seconds or greater (Straus et al 
2000). On spirometry, patients with COPD demonstrate a 
forced expiratory volume in one second (FEV1) to forced 
vital capacity (FVC) ratio of less than 0.70 following 
receipt of a bronchodilator (eg, albuterol 200–400 μg) 
(O’Donnell et al 2007; Rabe et al 2007). Once the diagnosis 
of COPD is made, severity is assessed using the post-
bronchodilator FEV1 value. An example of the severity classi-
ﬁ  cation scheme is shown in Figure 1 (O’Donnell et al 2007). 
Mild COPD is deﬁ  ned by a post-bronchodilator FEV1 that is 
80% of predicted or greater in the presence of an FEV1/FVC 
ratio of less than 70% and characteristic symptoms such as 
exertional dyspnea in most cases (Celli and MacNee 2004; 
Rabe et al 2007). However, some who meet the spirometric 
criteria of mild COPD may be asymptomatic. In one study 
of patients who were seen at a primary care ofﬁ  ce, over a 
third of ex- and current smokers who were diagnosed with 
mild COPD based on screening spirometry were asymp-
tomatic at the time of testing, while 2/3 of never smokers 
diagnosed with mild COPD were asymptomatic (Bednarek 
et al 2008). Thus, the prevalence of COPD based on physician 
or self-diagnosis likely under-estimates the prevalence of 
COPD based on spirometry (Buist et al 2007). A more liberal 
use of spirometry in primary care may increase the detection 
and diagnosis of COPD in the community.
Treatment goals
Although patients with mild COPD are at increased risk of 
respiratory infections and respiratory failure, COPD-related 
hospitalizations and deaths are relatively infrequent in 
this group of patients (Anthonisen et al 1994). Thus, dis-
similar to those with more severe disease, prevention of 
respiratory complications such as exacerbations and respi-
ratory mortality is not the primary goal in the treatment 
of mild COPD. Instead, treatment goals are focused on 
the following 3 domains: 1) relieving patient symptoms; 
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2) slowing the progression of disease; and 3) mitigating the 
risk for cardiovascular disease (CVD) and lung cancer, which 
are the leading causes of hospitalization and mortality in 
patients with mild COPD (Anthonisen et al 1994).
Treatment goal 1: relief 
of patient symptoms
The most common symptom in mild COPD is exertional 
dyspnea with or without chronic cough. In assessing 
these symptoms, physicians must rule out all other causes 
of dyspnea including cardiovascular de-conditioning, 
neuromuscular disease, interstitial lung disease, ischemic 
heart disease, congestive heart failure, pulmonary embo-
lism, anemia and pulmonary hypertension. A careful 
history and physical examination, accompanied by simple 
laboratory tests such as pulse oximetry, chest radiograph, 
electrocardiogram, complete blood count and spirometry 
are usually sufﬁ  cient in excluding other common causes of 
dyspnea. In a minority of cases, additional tests including 
incremental cardiopulmonary exercise testing, echocardio-
gram and computed tomography (CT) may be necessary. 
Once all causes of dyspnea have been ruled out and COPD 
is conﬁ  rmed by spirometry, management can be initiated.
Smoking cessation
Symptomatic treatment starts with smoking cessation for 
smokers with mild COPD. In a dose dependent manner, 
smoking induces cough and dyspnea and smoking cessation 
attenuates these symptoms (Stein et al 2005). Although the 
prevalence of smoking has declined over the past two decades 
in the US and other industrialized nations, 20% of adults in 
the western world continue to smoke. In the developing world, 
smoking rates are increasing with nearly 40% of adults smoking 
on a daily basis in certain jurisdictions (Ezzati and Lopez 2003). 
Although clinicians should encourage patients to stop smoking 
and provide practical advices in their clinic, these measures are 
generally ineffective, leading to smoking cessation in only about 
5% of smokers (Bailey 1985). This intervention, however, is 
more effective when offered at the time the diagnosis of COPD 
is made (Stratelis et al 2006). Another way to increase cessation 
rate is to convey the concept of “lung age” to the patients. Lung 
age is deﬁ  ned as the age of the average person who has the 
same FEV1 as that of the patient and can be calculated using 
the formula: lung age (for men) = 2.87 × height (in inches) 
− 31.25 × observed FEV1 (liters) − 39.375 and lung age (for 
women) = age = 3.56 × height (in inches) − 40 × observed 
FEV1 (liters) − 77.28 (Morris and Temple 1985). In the largest 
randomized trial of its kind, Parkes et al showed that smokers 
who received information regarding their “lung age” were 
twice as more likely to quit than smokers who received their 
raw FEV1 data (Parkes et al 2008). At 12 months of follow-up, 
the cessation rate was 14% in the lung age group versus 6% in 
the control group.
Comprehensive smoking cessation clinics consisting of 
physician services, cognitive and behavioral modiﬁ  cation 
programs, and nicotine replacement therapy achieve the 
best results (Schroeder 2005). Cognitive programs employ 
techniques such as distraction, positivism, relaxation, and 
mental imagery to modify patient’s attitude towards smoking 
(Schroeder 2005). Behavioral interventions, on the other 
hand, focus on breaking the smoking habit by avoiding 
smoking triggers such as drinking coffee or alcohol or 
associating with friends who smoke. Collectively, these 
methods are effective in fostering quitting in about 10% to 
15% of motivated smokers (Kanner et al 1999).
One of the cornerstones in smoking cessation is the use of 
nicotine replacement therapy (NRT). NRT has been expertly 
reviewed elsewhere (Molyneux 2004). The major goals of 
NRT are to 1) attenuate withdrawal symptoms, 2) eliminate 
craving; and 3) make smoking less rewarding. NRT generally 
doubles the cessation rate compared to physician advice alone 
(Molyneux 2004). High doses of NRT are more effective 
than lower doses but are fraught with more side effects 
(Schroeder 2005). However, for those patients refractory 
to the lower doses, higher doses should be considered. Side 
effects include insomnia, skin irritation (for patches), and 
early morning cravings for nicotine. There are 6 ways in 
which NRT can be administered: as a patch, gum, sublingual 
tablet, lozenge, nasal spray, or inhaler. The patches are the 
most common mode of delivery and are found in 16-hour 
(5, 10, 15 mg) or 24-hour (7, 14, 21 mg) formulations. The 
gums are also frequently used and they are packaged in 2- or 
4-mg pieces.
Non-nicotine based pharmacologic therapies are also 
available and are as effective as NRT in fostering smoking 
cessation. Anti-depressants and in particular bupropion 
significantly enhance cessation rates. Similar to NRTs, 
bupropion and nortryptylline double the quitting rates 
compared with advice alone (Hughes et al 2007). Bupropion 
should be prescribed at least 1 week before the cessation date, 
so that adequate blood levels can be achieved and continued 
for 2 to 3 months following cessation. There is insufﬁ  cient 
evidence to determine whether or not anti-depressants provide 
incremental beneﬁ  ts on cessation beyond that achieved by 
NRT alone. Serious side effects from anti-depressants are rela-
tively uncommon. The risk of seizures is about 0.1% with the International Journal of COPD 2008:3(4) 566
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use of bupropion (Hughes et al 2007). Thus, bupropion should 
be avoided in patients with a seizure disorder (Schroeder 
2005). Although there are ongoing concerns regarding the 
possible increased risk of suicides among those who take 
bupropion, there is insufﬁ  cient body of evidence to support 
this notion.
More recently α4β2 nicotinic acetylcholine receptor 
agonists (eg, varenicline) have been introduced into the 
market for smoking cessation (Gonzales et al 2006). 
Varenicline is a partial α4β2 nicotinic receptor agonist. 
It is approximately three times more effective in effect-
ing smoking cessation than is placebo (Cahill et al 2007). 
It should be started at 0.5 mg daily while the patient is still 
smoking and then escalated to 1 mg per day by the second 
week. The patient should quit smoking completely by week 2 
and the drug should be continued for another 12 weeks. The 
most common side effect of this drug is nausea, which can 
be mitigated by taking the drug following meals. Varenicline 
appears to be more effective than bupropion (odds ratio for 
smoking cessation, 1.66) (Cahill et al 2007). However, it 
should be used with extreme caution (if at all) in patients 
with a past history of severe depression or a psychosis as it 
has been rarely associated with major psychiatric adverse 
effects (Pumariega et al 2008).
Bronchodilators
For those who remain symptomatic despite smoking cessation, 
bronchodilators may be used to improve patient symptoms. 
If the symptoms are periodic, short-acting bronchodilators 
(eg, beta-2 agonists or anticholinergics) can be used on 
an as-needed basis. For those with persistent symptoms, 
short-acting bronchodilators may be used regularly (eg, 4 times 
a day) or, alternatively, long-acting bronchodilators may be 
used instead. All bronchodilators work by increasing expiratory 
flow, reducing dynamic hyperinflation and improving 
exercise capacity and quality of life of patients (Hanania and 
Donohue 2007). However, the improvement in symptoms and 
exercise capacity is not readily predictable from the spirometric 
response to bronchodilators. There are two major classes of 
bronchodilators: β2-agonists and anti-cholinergic agents.
β2-agonists
All β2-agonists act by binding to and stimulating cell surface 
β2-adrenoceptors, which belong to a seven transmembrane 
G-protein coupled receptor family. Upon ligand binding, 
the α-component of the G-protein dissociates and activates 
adenylate cyclase (Johnson 1998), which in turn stimulates 
the production of cyclic adenosine monophosphate, and 
activates protein kinase A (PKA). PKA then phosphorylates 
a number of intracellular regulatory proteins (Johnson 1998). 
Stimulation of the β2- adrenoreceptors can also inhibit 
histamine and cysteinyl-leukotriene release from mast cells, 
prevent plasma exudation from postcapillary venules, and 
modulate sensory neural outputs in the airways (Johnson 
1998). Thus, in addition their bronchodilatory properties, 
β2-agonists may have anti-inﬂ  ammatory effects.
There are two major categories of β2-agonists: short 
acting β2-agonists (SABA) and long-acting β2-agonists 
(LABA). SABAs have a rapid onset of action (1–3 minutes) 
and their pharmacologic effects last less than six hours 
(Rabe et al 2007). Thus, they provide quick relief of dyspnea 
and are best used as rescue medications for patients with 
intermittent symptoms. In patients with persistent symptoms, 
regular use of SABAs (usually four times a day) either 
alone or in combination (of β2-agonist and anticholinergic) 
is recommended. Of the SABAs, salbutamol (albuterol) is 
the most commonly used agent and can be delivered via a 
metered dose inhaler or a nebulizer. For patients with mild 
COPD who have symptoms refractory to SABAs, LABAs 
may be considered. The two most commonly used LABAs 
in clinical practice are salmeterol and formoterol. Both of 
these compounds have high afﬁ  nity for β2-adrenoreceptors. 
Salmeterol is considered a partial agonist because the ligand-
receptor coupling is incomplete. In contrast, formoterol binds 
completely to the β2-adrenoreceptor, making it a full agonist. 
Salmeterol binds to β2-adrenoreceptor in airway smooth 
muscle with an efﬁ  cacy of 65% compared to formoterol 
(Ball et al 1991). Despite these differences, clinically, they 
appear to have similar effectiveness. On average, formoterol 
provides faster relief of symptoms than does salmeterol but 
salmeterol may provide longer duration of relief (Johnson, 
1998). Although some safety concerns have been raised 
regarding their use in asthma (Martinez 2005; Salpeter 
et al 2006), LABAs appear to be safe in COPD (Calverley 
et al 2007).
Anticholinergics
Anticholinergic agents, on the other hand, reduce airway tone 
by blocking the muscarinic receptors that induce bronchial 
smooth muscle contraction. Ipratropium bromide is the 
prototypical short acting anticholinergic agent, which has a 
half-life of less than 6 hours (Rabe et al 2007). Tiotropium 
is a longer acting anticholinergic agent that is approximately 
10-fold more potent than ipratropium bromide. This is because 
tiotropium dissociates very slowly from lung muscarinic 
receptors and in airway smooth muscles demonstrates partial International Journal of COPD 2008:3(4) 567
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selectivity for the M3-receptors. Clinically, tiotropium 
provides bronchodilation for greater than 24 hours and thus 
is suitable for once-daily dosing (Barnes et al 1995).
Tiotropium has been largely tested in patients with 
moderate to severe disease. Clearly, in moderate to severe 
disease, tiotropium reduces patient symptoms, improves 
health-related quality of life, reduces exacerbations (Barr 
et al 2006), decreases dynamic hyperinﬂ  ation of the lungs 
(Maltais et al 2005) and increases exercise tolerance 
(Casaburi et al 2005). However, there is little information on 
the effectiveness of tiotropium in patients with mild disease. 
In one 12-week randomized controlled trial (N = 224; mean 
FEV1, 74% of predicted), patients with mild COPD who 
received tiotropium experienced a 118 mL improvement 
in FEV1 and required fewer daily doses of a short-acting 
β2-agonists compared to those who received placebo 
(Johansson et al 2008). However, symptom and quality of 
life scores were no different between the two groups.
Similarly, there is a large body of evidence indicating 
that LABA is effective in relieving symptoms and improving 
health status in patients with moderate to severe COPD 
(Calverley et al 2007; Sin et al 2003). However, as with 
tiotropium, there is a marked scarcity of information 
regarding their effectiveness in mild COPD. In general, 
while they improve lung function, they do not appear to 
have a major impact on patient symptoms or quality of 
life in mild COPD (Appleton et al 2006). Thus, LABAs 
cannot be recommended routinely for mild COPD except in 
patients who have persistent symptoms despite SABAs or 
in those who have frequent exacerbations requiring systemic 
corticosteroid therapy and/or hospital visits.
Inhaled glucocorticoids
Inhaled glucocorticoids have been used for COPD over 
the past 3 decades. Nevertheless, their exact role in COPD 
management remains uncertain. In the 1990s, several 
large-scale randomized controlled trials were conducted 
to clearly deﬁ  ne the beneﬁ  ts and the hazards of inhaled 
corticosteroids in the treatment of COPD. All of these 
studies were powered to determine whether or not inhaled 
corticosteroids modiﬁ  ed the rate of decline in FEV1. However, 
several studies also captured the effects of these drugs on 
patient symptoms. In one of the largest study of its kind, the 
Lung Health Study (LHS)-2 evaluated the effects of inhaled 
triamcinolone on symptoms in patients with mild to moderate 
COPD (mean FEV1, 68% of predicted) (Lung Health Study 
Group, 2000) . On average, the subjects were followed for 
40 months. Triamcinolone had no signiﬁ  cant effect on cough 
and sputum production (p = 0.26) but a signiﬁ  cant impact in 
reducing dyspnea (p = 0.02). Sixty-eight percent of patients 
in the triamcinolone arm did not complain of dyspnea by 
the end of the study, while 62% did not have dyspnea in the 
placebo arm (a difference of 6.7%). Importantly, compared 
with placebo, there was a 29% relative reduction in the number 
of patients who complained of difﬁ  culty breathing (p = 0.05), 
and a 35% relative reduction in the number of patients with 
wheezing in the group that took triamcinolone (Lung Health 
Study Group, 2000). In the Copenhagen City Heart Study 
(mean FEV1, 87% of predicted), similar to LHS-2, inhaled 
budesonide did not have a signiﬁ  cant impact on cough and 
sputum production (Vestbo et al 1999). Collectively, these 
data suggest that inhaled corticosteroids probably do not 
have any signiﬁ  cant effect on cough and sputum production; 
they appear to have a modest effect in reducing dyspnea. 
However, in view of the long-term safety concerns associated 
with inhaled corticosteroids including bone demineralization 
and skin bruising, they cannot be routinely recommended in 
patients with mild COPD. Inhaled corticosteroids may be 
considered for patients with dyspnea refractory to smoking 
cessation and bronchodilators.
Pulmonary rehabilitation
In COPD, patients experience dyspnea and exercise limitation 
because of impaired gas exchange, increased dead space 
ventilation and dynamic hyperinﬂ  ation (Oﬁ  r et al 2008). 
Additional demands are placed on the respiratory system 
by physical deconditioning and peripheral muscle dysfunc-
tion. Exercise training programs in COPD have the goal of 
improving cardiovascular ﬁ  tness, increasing aerobic capacity 
of muscles and decreasing symptoms. Pulmonary rehabilita-
tion programs have also been shown to decrease the number 
of exacerbations and shorten the length of hospital stay 
during an exacerbation (Hunter and King 2001; Nici et al 
2006). Although most of these studies were conducted in 
patients with moderate to severe disease, several studies were 
evaluated patients with mild COPD (Bianchi et al 2002; Clark 
et al 2000; Dourado et al 2006; Garrod et al 2004; Kamahara 
et al 2004; Karapolat et al 2007; Rossi et al 2005). Clinical 
outcomes were measured by activity endurance (6 minute 
walk test) as well as with a quality of life instrument such as 
the St Georges Respiratory Questionnaire (SGRQ). One study 
found that muscle function and oxygen utilization (VO2max, 
VTmax, paired t-test) improved after a 12-week rehabilitation 
program involving isokinetic strength training (Clark et al 
2000), while another showed improved exercise endurance 
with pulmonary rehabilitation (R2 = 0.146) (Eakin et al 1992). International Journal of COPD 2008:3(4) 568
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However, the beneﬁ  cial effects of pulmonary rehabilitation 
appear to be time-limited and wears off over time unless 
the exercise program is continued (Karapolat et al 2007). 
Additionally, pulmonary rehabilitation programs that are 
longer in duration appear to be superior to short programs. 
One study found that a 20-session course led to improved 
6 minute walk distance and better quality life compared with 
a 10-session course. Thus, pulmonary rehabilitation program 
should be considered for patients with mild COPD, who are 
symptomatic and are experiencing limitations in activity 
endurance and reduced quality of life.
Independent of symptoms all patients should be 
encouraged to exercise regularly (low to moderate intensity 
exercise for 30 minutes greater, at least 3 to 4 times per 
week) as regular physical activity independent of other 
factors is associated with slower progression of disease 
(Garcia-Aymerich et al 2007). Additionally, patients should 
receive dietary counseling to ensure that adequate amount 
of calories are consumed each day and the diet is enriched 
for fruits, vegetables and ﬁ  sh, which may decrease COPD 
progression (Varraso et al 2007).
Treatment goal 2: slow 
the progression of disease
Smoking cessation
The most commonly used metric for measuring disease 
progression in COPD is the rate of decline in lung function, 
as assessed by FEV1. Due to the intrinsic variability of the 
measurement, at least 3 FEV1 values measured over 3 years 
are needed to adequately assess progression. It is well 
known that smoking accelerates the decline in FEV1, while 
smoking cessation normalizes the rate of decline. In the 
Lung Health Study, which evaluated 5,800 smokers with 
mild to moderate COPD, smokers who continued to smoke 
lost on average 60 mL/year in FEV1 over a 5 year follow-up 
period. In contrast, sustained quitters lost 14 ml/year in 
FEV1 (Anthonisen et al 1994). Over 11 years of follow-up, 
sustained quitters lost 26 to 30 mL/year (or 0.23% to 0.40% of 
predicted/year) in FEV1, whereas intermittent quitters lost 
48 to 50 mL/year (or 0.91% to 1.02% of predicted/year) 
and continued smokers lost 60 to 64 mL/year (or 1.29 to 
1.44% of predicted/year) in FEV1 (Anthonisen et al 2002). 
Smoking cessation is the only proven method of retarding 
disease progression in COPD.
Inhaled glucocorticoids
In the 1990s, there was renewed enthusiasm for using inhaled 
corticosteroids to modify the natural history of COPD 
(Sin et al 2005a). Several long-term randomized controlled 
trials were performed in mostly mild to moderate COPD 
subjects. Collectively, these trials indicated that within the 
ﬁ  rst 6 months of therapy, inhaled corticosteroids increased 
FEV1 compared to placebo. The effect was most pronounced 
in female non-smokers. However, they did not modify the 
long-term decline in FEV1 (Soriano et al 2007).
Combination of inhaled glucocorticoids 
and LABAs
In moderate to severe COPD, LABAs and inhaled 
corticosteroids either by themselves or in combination 
have a modest effect on disease progression. In the 
TORCH (TOwards a Revolution in COPD Health) Study, 
which evaluated these medications in moderate to severe 
COPD, patients who received inhaled fluticasone or 
salmeterol experienced a slower decline in FEV1 (by 
13 mL/year) compared to those who received placebo 
(Calverley et al 2007). Patients who received a combina-
tion of ﬂ  uticasone and salmeterol demonstrated the slowest 
decline (by 16 mL/year). The effects of tiotropium on 
disease progression have been assessed in the UPLIFT 
trial (Understanding the Potential Long-Term Impacts 
on Function with Tiotropium) (Decramer et al 2004). 
The ﬁ  ndings of this trial are expected in the fall of 2008.
Treatment goal 3: reduce the risk 
of CVD and lung cancer related 
morbidity and mortality
In the Lung Health Study, which studied patients with 
mild to moderate COPD, the leading cause of hospital-
ization were CVDs, accounting for nearly 50% of all 
hospitalizations (Anthonisen et al 1994). Although deaths 
were rare, over 20% of all deaths were CVD in nature. 
In the National Health Examination Follow-up Survey, 
which sampled a representative mix of the US civilian 
adult population, baseline FEV1 was independent predictor 
of CVD hospitalization and mortality over 10 years of 
follow-up. Even within the “normal ranges” of FEV1 values, 
individuals who had the highest FEV1 were least likely to 
develop CVDs (see Figure 2), while those with reduced 
FEV1 values had higher risk of CVD (Sin et al 2005b). Mild 
COPD is associated with a 2-fold increased risk of CVD 
compared to individuals without COPD (Sin et al 2005b). 
Similarly, the risk of lung cancer is increased in mild COPD 
(Wasswa-Kintu et al 2005). Indeed, lung cancer is the most 
common cause of death in mild COPD, accounting for 1/3 of International Journal of COPD 2008:3(4) 569
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all deaths in this group of patients (Anthonisen et al 1994). 
The mechanisms by which mild COPD increase the risk 
of CVD and lung cancer are still a mystery. Inﬂ  ammation, 
oxidative stress, DNA mutation and shared risk factors are 
some of the common explanations.
Smoking cessation
Smoking cessation is the only proven of way of reducing CVD 
and lung cancer in COPD patients. CVD risk is particularly 
responsive to smoking cessation. Compared to continued smok-
ers, CVD mortality is reduced by over 60% in sustained quitters 
(Anthonisen et al 2005). Interestingly, the CVD mortality risk is 
reduced by 54% even among intermittent quitters. In contrast, 
the risk of lung cancer mortality is only reduced by 20% among 
intermittent quitters compared to continued smokers, although 
it is reduced by ∼55% in sustained quitters (see Figure 3).
Glucocorticoids
Inhaled corticosteroids may modify long-term risk of CVD 
and lung cancer in patients with COPD. Using a large 
health administrative database from Veterans Affairs, 
Parimon and colleagues reported that inhaled corticosteroids 
(1200 μg/day of triamcinolone, which is equivalent 
to 180 μg/day of beclomethasone) were associated with 
a 61% reduction in the risk of lung cancer (Parimon et al 
2007). In a randomized control trial, Lam and colleagues 
evaluated the effects of inhaled budesonide on bronchial 
dysplasia in 113 smokers (with relatively normal lung func-
tion) over 6 months. Although there was no signiﬁ  cant effect 
of inhaled budesonide on disease progression, it signiﬁ  cantly 
reduced prostaglandin E2 levels in the bronchoalveolar 
lavage ﬂ  uid and expression of p53 and BCL-2 in bronchial 
tissues. Inhaled budesonide also reduced the number of 
pulmonary nodules detected on computed tomographic 
(CT) scans (Lam et al 2004). In the Inhaled Steroid Effects 
Evaluation in COPD (ISEEC) study, which was a pooled 
analysis of 7 large trials of inhaled corticosteroids in COPD, 
there was a trend towards lower cancer mortality in the 
group that received corticosteoroids compared with placebo 
(relative risk, 0.55; 95% conﬁ  dence interval, 0.29 to 1.03) 
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(Sin et al 2005a). Long-term large-scale trials are needed to 
conﬁ  rm these early observations and determine the effects of 
inhaled corticosteroids on lung cancer in COPD patients.
Inhaled corticosteroids have also been associated with 
reduced risk of CVD. Huiart and colleagues, using a large 
administrative database from Saskatchewan, reported that 
COPD patients who used 50 to 200 μg/day of beclomethasone 
(or equivalent) were 32% less likely to experience myocardial 
infarction than those who did not use any inhaled corticosteroids 
(Huiart et al 2005). Macie and colleagues, using another large 
administrative database from Manitoba, showed that COPD 
patients who used inhaled corticosteroids were nearly 40% 
less likely to suffer a cardiac mortality than those who did not 
(Macie et al 2006). In EUROSCOP (European Respiratory 
Society’s study on Chronic Obstructive Pulmonary Disease), 
1,277 patients with mild to moderate COPD (mean FEV1, 77% of 
predicted) were assigned to inhaled budesonide or placebo for 
3 years. A post hoc analysis of the safety data demonstrated 
that patients assigned to inhaled budesonide had 42% fewer 
ischemic cardiac events (deﬁ  ned as angina pectoris, myocardial 
infarction, coronary artery disease, or myocardial infarction) 
compared to those assigned to placebo (p = 0.048) (Lofdahl 
et al 2007). However, these data must be interpreted cautiously 
because the baseline event rate was low (4.2%).
Vaccination
COPD independently contributes to mortality and increased 
length of stay in hospitals from community-acquired pneu-
monia (Restrepo et al 2006). Inﬂ  uenza vaccination reduces 
overall mortality by 70% in patients with chronic lung disease 
(odds ratio 0.30, p  0.001) (Nichol et al 1999a). However, 
it does not appear to modify the rate of exacerbations in 
patients with mild COPD (Menon et al 2008; Poole et al 
2006). Pneumococcal vaccination is also associated with 
reduced risk of hospitalizations from pneumonia as well 
as all-cause mortality beyond that achieved with inﬂ  uenza 
vaccination (Nichol et al 1999b).
Summary and conclusion
COPD is a treatable disease. A short synopsis of a management 
strategy for mild COPD is provided in Table 1. The corner-
stone of management is smoking cessation, which not only 
improves patient symptoms but is the only proven way of 
modifying its natural history and reducing mortality. Vac-
cinations for inﬂ  uenza and pneumococcus may reduce mor-
bidity and mortality from community-acquired pneumonia. 
In patients who have intermittent symptoms, short-acting 
bronchodilators may be used on an as “as-needed” basis, 
while for patients with more persistent symptoms, these drugs 
0
10
20
30
40
50
60
70
80
90
100
Sustained Quitters Intermittent 
Quitters
Continued Smokers
%
 
R
e
d
u
c
t
i
o
n
 
O
v
e
r
 
1
4
.
5
 
Y
e
a
r
s
CVD Mortality
Lung Cancer Mortality
Figure 3 The effect of smoking cessation on cardiovascular and lung cancer mortality (derived from Anthonisen et al 2005).
The Y-axis plots the relative risk reduction in mortality from each of the causes relative continued smokers. Sustained quitters are deﬁ  ned as those who stopped smoking 
entirely during the follow-up period. Intermittent quitters are those who quit and re-started smoking.International Journal of COPD 2008:3(4) 571
COPD management
may be given regularly (eg, 4 times a day). In patients whose 
symptoms are refractory to short-acting bronchodilators, 
long-acting bronchodilators may be provided. LABAs and 
tiotropium appear to have similar effectiveness for patients 
with mild disease. Pulmonary rehabilitation regimens may 
also improve exercise tolerance and quality of life. In a 
small minority of patients who remain symptomatic despite 
long-acting bronchodilators, a combination of inhaled 
corticosteroids and LABAs may be considered. Although 
inhaled corticosteroids by themselves reduce dyspnea and 
improve lung function, they probably should not be the 
sole therapy for patients with mild disease in view of their 
potential long-term side effects. Inhaled corticosteroids do 
not appear to modify the long-term decline in FEV1; however, 
there are emerging data suggesting their potential usefulness 
in reducing the risk of lung cancer and CVD, which are 
the leading causes of mortality and hospitalization in mild 
COPD. However, before this notion can be fully accepted, 
large-scale randomized controlled trials are needed to vali-
date these early ﬁ  ndings.
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